Cyclacel Pharmaceuticals Inc. (CYCC) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Cyclacel Pharmaceuticals ...

    NASDAQ: CYCC · Real-Time Price · USD
    6.37
    -0.40 (-5.91%)
    At close: Sep 11, 2025, 3:59 PM

    Cyclacel Pharmaceuticals Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 43K 420K n/a n/a
    Cost of Revenue
    		 n/a n/a 32K 43K
    Gross Profit
    		 43K 420K -32K -43K
    Operating Income
    		 -12M -25.45M -27.66M -22.94M
    Interest Income
    		 12K 266K 210K 16K
    Pretax Income
    		 -11.99M -25.55M -25.91M -22.18M
    Net Income
    		 -11.21M -22.55M -21.2M -18.89M
    Selling & General & Admin
    		 5.39M 6.72M 7.38M 7.46M
    Research & Development
    		 6.66M 19.16M 20.27M 14.93M
    Other Expenses
    		 n/a n/a n/a n/a
    Operating Expenses
    		 12.05M 25.87M 27.66M 22.39M
    Interest Expense
    		 n/a n/a n/a n/a
    Selling & Marketing Expenses
    		 n/a n/a n/a n/a
    Cost & Expenses
    		 12.05M 25.87M 27.66M 22.39M
    Income Tax Expense
    		 -782K -3M -4.72M -3.85M
    Shares Outstanding (Basic)
    		 8.31M 797.63K 750.38K 595.07K
    Shares Outstanding (Diluted)
    		 8.31M 797.63K 750.38K 595.07K
    EPS (Basic)
    		 -1.36 -28.67 -28.5 -32.1
    EPS (Diluted)
    		 -1.36 -28.67 -28.5 -32.1
    EBITDA
    		 -12M -25.42M -27.62M -22.69M
    EBIT
    		 -12M -25.45M -27.66M -22.73M
    Depreciation & Amortization
    		 6K 31K 32K 43K

    Add to Watchlist